Presented two academic papers at IFSCC 2022, cosmetic researchers conference held in London

Mediplus Pharma Corporation (CEO: Kenji Ito, Headquarters: Shibuya, Tokyo) presented two academic papers about ozonized glycerin (glycenergy)*, a novel glycerin compound, at the international cosmetics researchers conference, IFSCC 2022 @ London (International Federation of Societies of Cosmetic Chemists Annual Congress, September 19-22, 2022).

Read more

The world’s leading academic journal on cosmetic dermatology「Journal of Cosmetic Dermatology」has accepted Mediplus Pharma’s article ” Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin“”

Read more

sid portland22

Mediplus Pharma is presenting posters at Society for Investigative Dermatology(SID)annual meeting 2022

Mediplus Pharma, Inc. (CEO: Kenji Ito, Head Office: Shibuya-ku, Tokyo,JAPAN) made a scientific presentation at the annual meeting of the Society for Investigative Dermatology (May 18-21, 2022, Portland, USA), which is considered the world’s highest-level society in dermatological research.

Title:Novel glycerin compounds improve skin health

Read more

New ways to reduce facial age spots. Japanese Pharmaceutical R&D company Mediplus Pharma found the new ability of “High performance Glycerin” Effective in 92% of people after 8 weeks of continuous use.


Mediplus Pharma, Inc. (CEO: Kenji Ito, Head Office: Shibuya-ku, Tokyo,JAPAN) confirmed that cosmetics containing its patented ingredient, high performance ozonized glycerin, have the effect of reducing melanin (age spots) in the epidermis, and filed a new application patent which claimed melanin decomposition.

Read more